| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
Activation of GLP-1 receptor signalling alleviates cellular stresses and improves beta cell function in a mouse model of Wolfram syndrome
|
Kondo, Manabu
|
|
2018
|
61 |
10 |
p. 2189-2201
|
article
|
| 2 |
A novel dual PPAR-γ agonist/sEH inhibitor treats diabetic complications in a rat model of type 2 diabetes
|
Hye Khan, Md Abdul
|
|
2018
|
61 |
10 |
p. 2235-2246
|
article
|
| 3 |
Development of SGLT1 and SGLT2 inhibitors
|
Rieg, Timo
|
|
2018
|
61 |
10 |
p. 2079-2086
|
article
|
| 4 |
Empagliflozin is associated with improvements in liver enzymes potentially consistent with reductions in liver fat: results from randomised trials including the EMPA-REG OUTCOME® trial
|
Sattar, Naveed
|
|
2018
|
61 |
10 |
p. 2155-2163
|
article
|
| 5 |
Genome-wide association study of coronary artery disease among individuals with diabetes: the UK Biobank
|
Fall, Tove
|
|
2018
|
61 |
10 |
p. 2174-2179
|
article
|
| 6 |
Gluten intake and risk of type 2 diabetes in three large prospective cohort studies of US men and women
|
Zong, Geng
|
|
2018
|
61 |
10 |
p. 2164-2173
|
article
|
| 7 |
Identification of a missense variant in the WFS1 gene that causes a mild form of Wolfram syndrome and is associated with risk for type 2 diabetes in Ashkenazi Jewish individuals
|
Bansal, Vikas
|
|
2018
|
61 |
10 |
p. 2180-2188
|
article
|
| 8 |
MANF protects human pancreatic beta cells against stress-induced cell death
|
Hakonen, Elina
|
|
2018
|
61 |
10 |
p. 2202-2214
|
article
|
| 9 |
More work is needed to better understand diabetes distress as a predictor of all-cause mortality in type 2 diabetes
|
Lindekilde, Nanna
|
|
2018
|
61 |
10 |
p. 2247-2248
|
article
|
| 10 |
Physiology of renal glucose handling via SGLT1, SGLT2 and GLUT2
|
Ghezzi, Chiara
|
|
2018
|
61 |
10 |
p. 2087-2097
|
article
|
| 11 |
Programming of central and peripheral insulin resistance by low birthweight and postnatal catch-up growth in male mice
|
Berends, Lindsey M.
|
|
2018
|
61 |
10 |
p. 2225-2234
|
article
|
| 12 |
Sex differences in the association between diabetes and cancer: a systematic review and meta-analysis of 121 cohorts including 20 million individuals and one million events
|
Ohkuma, Toshiaki
|
|
2018
|
61 |
10 |
p. 2140-2154
|
article
|
| 13 |
SGLT inhibitor adjunct therapy in type 1 diabetes
|
McCrimmon, Rory J.
|
|
2018
|
61 |
10 |
p. 2126-2133
|
article
|
| 14 |
SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review
|
Verma, Subodh
|
|
2018
|
61 |
10 |
p. 2108-2117
|
article
|
| 15 |
SGLT2 inhibitors: the future for treatment of type 2 diabetes mellitus and other chronic diseases
|
Wanner, Christoph
|
|
2018
|
61 |
10 |
p. 2134-2139
|
article
|
| 16 |
The actions of SGLT2 inhibitors on metabolism, renal function and blood pressure
|
Thomas, Merlin C.
|
|
2018
|
61 |
10 |
p. 2098-2107
|
article
|
| 17 |
The bark giving diabetes therapy some bite: the SGLT inhibitors
|
Marshall, Sally M.
|
|
2018
|
61 |
10 |
p. 2075-2078
|
article
|
| 18 |
Up front
|
|
|
2018
|
61 |
10 |
p. 2073-2074
|
article
|
| 19 |
Use of SGLT2 inhibitors in type 2 diabetes: weighing the risks and benefits
|
Lupsa, Beatrice C.
|
|
2018
|
61 |
10 |
p. 2118-2125
|
article
|
| 20 |
Use of the PET ligand florbetapir for in vivo imaging of pancreatic islet amyloid deposits in hIAPP transgenic mice
|
Templin, Andrew T.
|
|
2018
|
61 |
10 |
p. 2215-2224
|
article
|
Journal description